Retatrutide vs SS-31

Retatrutide and SS-31 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

Retatrutide is a novel investigational peptide acting as a triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. Developed by Eli Lilly, it shows promise in addressing obesity and metabolic disorders. In a Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), participants receiving a 12 mg dose experienced a substantial mean body weight reduction of 24.2% over 48 weeks, with all subjects achieving at least 5% weight loss. The ongoing Phase 3 TRIUMPH trials, particularly TRIUMPH-4, aim to further validate these findings, with preliminary results indicating an average weight loss of up to 71.2 lbs and associated relief from osteoarthritis pain. Anticipated FDA approval is projected for 2027-2028. Overall, Retatrutide's multifaceted approach not only targets weight management but may also enhance glycemic control in individuals with type 2 diabetes, reflecting its potential as a comprehensive therapeutic option.

SS-31, also known as Elamipretide, is a mitochondria-targeted tetrapeptide that binds selectively to cardiolipin within the inner mitochondrial membrane. This interaction stabilizes the cristae structure, which is critical for mitochondrial function. Developed by Stealth BioTherapeutics, SS-31 is under investigation for various conditions, including mitochondrial diseases, heart failure, and age-related mitochondrial dysfunction. Clinical trials, such as the Phase I–III TAZPOWER trial, have explored its efficacy for specific conditions like Barth syndrome. Evidence from these studies suggests that SS-31 may improve mitochondrial function and reduce cardiac dysfunction, potentially offering therapeutic benefits for patients with compromised mitochondrial health. Additionally, its role in addressing age-related decline in mitochondrial function hints at possible anti-aging effects, although further research is needed to substantiate these claims.

Both Retatrutide and SS-31 are being investigated within the realm of metabolic health, contributing to the understanding of how peptides can influence metabolic processes. Retatrutide is specifically being studied for its efficacy in weight management, leveraging its action on multiple hormone receptors to promote significant weight loss and improve metabolic parameters. In contrast, SS-31 is being explored for its potential in anti-aging research, particularly regarding its ability to enhance mitochondrial function and mitigate age-related decline. This divergence in application highlights the unique benefits each peptide may offer to researchers focusing on different aspects of metabolic health and longevity.

In terms of safety profiles, Retatrutide has been associated with gastrointestinal side effects, which are dose-related and observed in 13-63% of participants across various dose groups. Common adverse events include nausea, vomiting, diarrhea, and constipation, primarily classified as mild to moderate. Notably, a lower starting dose (2 mg) may help mitigate these gastrointestinal events compared to a higher initial dose (4 mg). Additionally, dose-dependent increases in heart rate were recorded, peaking at 24 weeks before declining. Conversely, SS-31 has demonstrated a generally favorable safety profile in clinical trials, with mild adverse effects such as headaches, dizziness, and nausea reported. Importantly, no significant safety signals were identified in the Phase I/II trials, suggesting that SS-31 may be well-tolerated across the tested dose ranges.